IN OVO CARCINOGENICITY ASSAY (IOCA)

卵内致癌性测定（IOCA）

• 批准号: 6143494
• 负责人: George L. DeGeorge
• 金额: $ 9.98万
• 依托单位: MB RESEARCH LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-18 至 2003-03-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6143494
• 关键词: DNA damage; aflatoxins; alternatives to animals in research; bioassay; carcinogen testing; diethylnitrosamine; egg /ovum; gel electrophoresis; mutagens; technology /technique development; turkeys

Carcinogenicity testing of substances is currently assessed via costly bioassays utilizing rodents in two year studies. The objective of this project is to develop an alternative assay which is performed on avian embryos as a screening test for carcinogenicity. The in ovo carcinogenicity assay (IOCA), conducted in fertilized turkey eggs, which addresses the three R's (reduction, refinement and replacement) of animal testing. The IOCA has numerous advantages over the rodent bioassay, including: 1) it is a rapid test, requiring a maximum of 24 days to perform; 2) testing does not require use of any mammals; 3) testing is performed on eggs, which are kept in incubators, requiring less space and equipment than animal facilities; 4) dose amounts are small, which reduces exposure of humans to potential carcinogens; and 5) cost of analysis is greatly reduced when compared to traditional carcinogenicity testing. We propose to demonstrate the utility of the IOCA as an alternative carcinogenicity assay by testing known carcinogens and comparing the results to those from two year rodent bioassays. By demonstrating the predictivity and sensitivity of IOCA to identify carcinogenic substances, we will establish the feasibility of IOCA as a commercially viable technology. PROPOSED COMMERCIAL APPLICATIONS: MB Research will offer the IOCA to the pharmaceutical, biotech, cosmetic, chemical and consumer products industries. We currently perform standard rodent bioassays and accelerated rodent carcinogenesis studies, as well as several egg-based studies for our clients. A survey of our clients indicates a demand for an alternative test that allows for rapid, inexpensive screening of potential carcinogenic substances. Thus, we are uniquely positioned to fulfill this industry demand and can provide this technology to a receptive client base, capturing a significant portion of the testing market.

目前，物质的致癌性测试是通过为期两年的研究，利用啮齿动物进行昂贵的生物测定来评估的。该项目的目标是开发一种替代检测方法，对禽类胚胎进行致癌性筛查测试。在受精火鸡蛋中进行的卵内致癌性测定 (IOCA)，解决了动物试验的 3R（减少、细化和替代）问题。与啮齿动物生物测定相比，IOCA 具有许多优势，包括：1) 它是一种快速测试，最多需要 24 天进行； 2）测试不需要使用任何哺乳动物； 3) 对保存在孵化器中的鸡蛋进行测试，与动物设施相比，需要更少的空间和设备； 4）剂量小，减少了人体对潜在致癌物的接触； 5）与传统致癌性检测相比，分析成本大大降低。我们建议通过测试已知的致癌物并将结果与​​两年啮齿动物生物测定的结果进行比较来证明 IOCA 作为替代致癌性测定的实用性。通过证明 IOCA 识别致癌物质的预测性和敏感性，我们将确定 IOCA 作为商业上可行的技术的可行性。拟议的商业应用：MB Research 将为制药、生物技术、化妆品、化学和消费品行业提供 IOCA。我们目前为客户进行标准啮齿动物生物测定和加速啮齿动物致癌研究，以及几项基于鸡蛋的研究。对我们客户的一项调查表明，需要一种替代测试，能够快速、廉价地筛查潜在的致癌物质。因此，我们在满足这一行业需求方面处于独特的地位，并且可以向愿意接受的客户群提供这项技术，从而占领测试市场的很大一部分。